Shantou University Medical College, Shantou, Guangdong 515041, China; Department of Urology, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China.
Department of Urology, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Anhui Medical University, Hefei, Anhui 230032, China.
Pathol Res Pract. 2021 Nov;227:153625. doi: 10.1016/j.prp.2021.153625. Epub 2021 Sep 24.
The aim of the study was to identify serum microRNAs (miRNAs) as potential biomarkers for screening renal cell carcinoma.
The study was divided into three stages, including screening stage, training stage, and validation stage. In the screening stage, we examined the expression of 30 serum miRNAs from healthy controls (HCs) and renal cell carcinoma (RCC) patients. We further studied the dysregulated miRNAs in training (30 RCC and 26 HCs) and validation (73 RCC and 80 HCs) stages. We estimated the diagnostic value of miRNAs by receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC). Finally, bioinformatics analysis were performed towards target genes of differentially expressed miRNAs.
Six serum miRNAs (miR-17-5p, miR-20a-5p, miR-21-5p, miR-150-5p, miR-145-5p and miR-146a-5p) in RCC patients were obviously differentially expressed compared to those in HCs in training stage and validation stage. To increase diagnostic value, we combined these six serum miRNAs and made a four-microRNA (miR-21-5p, miR-150-5p, miR-145-5p and miR-146a-5p) panel, and AUC of the panel was 0.938 (95% CI: 0.889-0.971; sensitivity=90.79%, specificity=93.75%). The genes targeted by these miRNAs were suggested that they may be involved in the process of cancers by the bioinformatics analysis.
Our study was performing a four-microRNA panel in serum for screening enal cell carcinoma. The four-miRNA panel (miR-21-5p, miR-150-5p, miR-145-5p and miR-146a-5p) may be perform as a biomarker without invasiveness for RCC screening.
本研究旨在寻找血清 microRNAs（miRNAs）作为筛选肾细胞癌的潜在生物标志物。
研究分为三个阶段，包括筛选阶段、训练阶段和验证阶段。在筛选阶段，我们检测了健康对照（HCs）和肾细胞癌（RCC）患者血清中 30 种 miRNA 的表达情况。我们进一步研究了训练（30 例 RCC 和 26 例 HCs）和验证（73 例 RCC 和 80 例 HCs）阶段中失调的 miRNA。我们通过接受者操作特征（ROC）曲线和 ROC 曲线下面积（AUC）来评估 miRNA 的诊断价值。最后，对差异表达 miRNA 的靶基因进行了生物信息学分析。
与训练和验证阶段的 HCs 相比，RCC 患者的 6 种血清 miRNA（miR-17-5p、miR-20a-5p、miR-21-5p、miR-150-5p、miR-145-5p 和 miR-146a-5p）表达明显不同。为了提高诊断价值，我们将这 6 种血清 miRNA 组合成一个四 miRNA（miR-21-5p、miR-150-5p、miR-145-5p 和 miR-146a-5p）panel，该 panel 的 AUC 为 0.938（95%CI：0.889-0.971；灵敏度=90.79%，特异性=93.75%）。通过生物信息学分析，这些 miRNA 靶向的基因表明它们可能参与了癌症的发生过程。
本研究在血清中进行了一个四 miRNA 面板筛选肾细胞癌。四 miRNA 面板（miR-21-5p、miR-150-5p、miR-145-5p 和 miR-146a-5p）可能作为一种无创伤性的 RCC 筛查标志物。
